Future clinical studies are imperative to further clarify HLJ1 expression and the underlying key pathways in both tumor and adjacent normal tissues from HCC patients, potentially opening new avenues for therapeutic intervention. This evidence concerns the gene DNAJB4 and hepatocellular carcinoma.